1. Home
  2. BKE vs ADPT Comparison

BKE vs ADPT Comparison

Compare BKE & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Buckle Inc. (The)

BKE

Buckle Inc. (The)

HOLD

Current Price

$41.95

Market Cap

2.7B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$21.28

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKE
ADPT
Founded
1948
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.7B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
BKE
ADPT
Price
$41.95
$21.28
Analyst Decision
Hold
Strong Buy
Analyst Count
1
9
Target Price
$53.00
$17.78
AVG Volume (30 Days)
491.0K
4.0M
Earning Date
05-22-2026
05-05-2026
Dividend Yield
7.96%
N/A
EPS Growth
6.43
63.89
EPS
0.92
N/A
Revenue
$1,297,835,000.00
$276,976,000.00
Revenue This Year
$5.10
$3.98
Revenue Next Year
$4.99
$22.72
P/E Ratio
$45.86
N/A
Revenue Growth
6.58
54.77
52 Week Low
$40.93
$9.96
52 Week High
$61.69
$22.80

Technical Indicators

Market Signals
Indicator
BKE
ADPT
Relative Strength Index (RSI) 36.45 66.83
Support Level N/A $15.08
Resistance Level $45.81 N/A
Average True Range (ATR) 1.34 1.27
MACD -0.00 0.33
Stochastic Oscillator 25.56 76.67

Price Performance

Historical Comparison
BKE
ADPT

About BKE Buckle Inc. (The)

Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: